ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass

March 29, 2013

In Brief: Garb Raps “Hostility Of Executive Branch”; Hew Considers Allowing Grants For Industry

April 25, 1980

Cullen To Leave NCI, Will Become Director Of AMC Cancer Center; Nixon May Join ACS

April 14, 1989

National Cancer Policy Board calls for public-private partnership for R&D in pediatric cancer drugs.

April 22, 2005

Funding Opportunities: Aging Institute Offers Program Announcement

February 6, 1998

Van Potter Wins Bristol-Myers Award

April 24, 1981